Citation
Yu, Fei, et al. "Receptor-binding Domain-specific Human Neutralizing Monoclonal Antibodies Against SARS-CoV and SARS-CoV-2." Signal Transduction and Targeted Therapy, vol. 5, no. 1, 2020, p. 212.
Yu F, Xiang R, Deng X, et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):212.
Yu, F., Xiang, R., Deng, X., Wang, L., Yu, Z., Tian, S., Liang, R., Li, Y., Ying, T., & Jiang, S. (2020). Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy, 5(1), 212. https://doi.org/10.1038/s41392-020-00318-0
Yu F, et al. Receptor-binding Domain-specific Human Neutralizing Monoclonal Antibodies Against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020 Sep 22;5(1):212. PubMed PMID: 32963228.
TY - JOUR
T1 - Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
AU - Yu,Fei,
AU - Xiang,Rong,
AU - Deng,Xiaoqian,
AU - Wang,Lili,
AU - Yu,Zhengsen,
AU - Tian,Shijun,
AU - Liang,Ruiying,
AU - Li,Yanbai,
AU - Ying,Tianlei,
AU - Jiang,Shibo,
Y1 - 2020/09/22/
PY - 2020/7/9/received
PY - 2020/9/3/accepted
PY - 2020/8/28/revised
PY - 2020/9/23/entrez
PY - 2020/9/24/pubmed
PY - 2020/10/7/medline
SP - 212
EP - 212
JF - Signal transduction and targeted therapy
JO - Signal Transduct Target Ther
VL - 5
IS - 1
N2 - The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.
SN - 2059-3635
UR - https://www.unboundmedicine.com/medline/citation/32963228/Receptor_binding_domain_specific_human_neutralizing_monoclonal_antibodies_against_SARS_CoV_and_SARS_CoV_2_
DB - PRIME
DP - Unbound Medicine
ER -